Tuesday, 9 February 2010
Nick Evans
PHARMAXIS’ early-stage pipeline has received a boost, with the next cab off the company’s drug ranks clearing its first Phase 1 trial. Pharmaxis announced results from the 40-patient trial on pulmonary fibrosis drug PXS25 this morning, saying the drug is “safe and well tolerated”.
You are not logged in or not authorised to view this page.
Get Your FREE 30 Day Trial Now!
|
|
|
OR
Click here to read the rest of today's news stories.
|
